• Lymphocytes are particularly rich in FKBP51 (FKBP5gene), an immunophilin better known as the intracellular receptor for FK506 and rapamycin. Melanoma/immune-cell interaction, through PD-L1/PD1, generates FKBP5 splicing, producing a lower molecular weight FKBP51 form, termed FKBP51s. • Tregs is a heterogeneous population with respect to their immunosuppressive capability, which is usually increased in melanoma patients. FKBP51s is associated with a highly metabolically active profile of Tregs with strong suppressive capability. • Melanoma patients that benefit from immune-checkpoint targeted therapy are recognizable by an expansion of FKBP51s+Treg subset which may be involved in de-activation of stimulatory co-signalling pathways, in support of tumor immune evasion.
A novel Treg subset involved in melanoma immune evasion / Romano, M. F.. - (2019). (Intervento presentato al convegno World Immunotherapy Congress tenutosi a Basel Congress Centre, Basel, Switzerland nel 15-17 ottobre 2019).
A novel Treg subset involved in melanoma immune evasion
Romano M. F.
2019
Abstract
• Lymphocytes are particularly rich in FKBP51 (FKBP5gene), an immunophilin better known as the intracellular receptor for FK506 and rapamycin. Melanoma/immune-cell interaction, through PD-L1/PD1, generates FKBP5 splicing, producing a lower molecular weight FKBP51 form, termed FKBP51s. • Tregs is a heterogeneous population with respect to their immunosuppressive capability, which is usually increased in melanoma patients. FKBP51s is associated with a highly metabolically active profile of Tregs with strong suppressive capability. • Melanoma patients that benefit from immune-checkpoint targeted therapy are recognizable by an expansion of FKBP51s+Treg subset which may be involved in de-activation of stimulatory co-signalling pathways, in support of tumor immune evasion.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
